<unk>  should not be used in people with active malignancy, any stage of diabetic eye disease in which high blood sugar levels cause damage to blood vessels in the retina, acute critical illness, or those with acute respiratory failure, because of the increased risk of mortality with use of pharmacologic doses of<unk>  in critically ill individuals without growth hormone deficiency.
Somapacitan
Meptazinol
Truenat
Sesquimustard
Propylpyrazoletriol
Lesinurad
Lazaretto
Ladostigil